Authors
Latest:
Value of Collaboration in Managing Patients With Metastatic RCCClosing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Latest:
Michael Szarek, PhD, on Research Areas of Focus for Tivozanib in RCCThe expert from SUNY Downstate Medical Center spoke about areas of research for renal cell carcinoma which he believes deserve further attention.
Latest:
When Melanoma Spreads to the Brain: Michael’s StoryThis is an actor portrayal of a hypothetical patient profile developed for educational purposes based on characteristics of patients with multiple myeloma as seen in clinical practice. The hypothetical case was co-developed by staff medical writers with Cancer Network/ONN.”
Latest:
Oncology On-The-Go Podcast: SGO 2023 RecapExperts from UCLA Health discuss key data presented at The Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer and how they may apply to clinical practice.
Latest:
Proactive Care in ALK-Positive NSCLC: Adverse Effect Counseling, Monitoring, and ManagementPanelists discuss how proactive monitoring for ALK inhibitor adverse effects through regular lipid panels, liver function tests, and patient education about red flag symptoms like bradycardia or cognitive changes enables early intervention and successful dose management.
Latest:
Looking Forward: Advice for Clinicians and Discussing Unmet Needs in the R/R MM LandscapeDr. Joshua Richter and Dr. Peter Forsberg close their discission with thoughtful advice for clinicians regarding the current and future treatment of patients with R/R MM.
Latest:
Key Takeaways in CAR-T Therapy for Multiple MyelomaPanelists discuss a clinical scenario involving a 56-year-old male man with myeloma and del 17p deletion, treated with RVD induction, auto transplant, and lenalidomide maintenance, who relapsed after 2 years and is now referred to discuss chimeric antigen receptor (CAR) CAR-T versus vs standard therapy, sharing key takeaways and pearls from the case.
Latest:
Face-Off: Award Presentation CeremonyFollowing a spirited debate, Joshua K. Sabari, MD, presents the winning team with the coveted title of victors of this CancerNetwork® Face-Off event.
Latest:
Dostarlimab/Chemo Yields “Unprecedented” OS in dMMR Endometrial CancerDostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Latest:
Oncology Peer Review On-The-Go: Routine Breast Cancer Screening in Average-Risk Women Younger Than 50 YearsCancerNetwork’s latest podcast episode features a conversation with Anath Ravi, PhD, of MOLLI Surgical and Randy Miles, MD, MPH, of Massachusetts General Hospital on the risks and benefits of breast cancer screening for average-risk women under the age of 50 years.
Latest:
Making Intervention Accessible for All Li-Fraumeni Syndrome PopulationsMichael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Best Practices for the Medical Oncology BoardsA group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
‘Future Is Bright’ With Bispecifics for Relapsed/Refractory MyelomaAn expert from Vanderbilt University Medical Center says that patients with relapsed/refractory multiple myeloma may be able to live a normal life following response to salvage treatment with bispecific monoclonal antibodies.
Latest:
Future Perspectives and Unmet Needs in Multiple MyelomaThe expert panel concludes their discussion by examining the unmet needs and future for the treatment landscape in multiple myeloma.
Latest:
Minimal Residual Disease–Directed Adjuvant Therapy for Patients With Early-Stage Colon Cancer: CIRCULATE-USIbrahim Halil Sahin, MD, and colleagues, explore, the CIRCULATE-US (NRG-GI008; NCT05174169) investigating postoperative ctDNA dynamics in early-stage colon cancer for treatment selection.
Latest:
Face-Off: Award Presentations and Event ConclusionJudy concludes the event and presents the awards.
Latest:
CLM in GALAXY: MRD Predicts Adjuvant Therapy Benefit and PrognosisPanelists discuss how minimal residual disease (MRD) detection in patients with colorectal liver metastases (CLM) in the GALAXY study predicts both the benefit of adjuvant therapy and overall prognosis, potentially guiding more personalized treatment decisions.
Latest:
Matthew Krebs, MB, PhD, Reviews the Next Steps for Subcutaneous Amivantamab in Solid TumorsMatthew Krebs, MB, PhD, spoke about how subcutaneous amivantamab can best be utilized in future clinical trials.
Latest:
Closing Thoughts, Future Perspectives, and Key Takeaways in the Treatment of Epithelioid SarcomaPanelists discuss how early recognition, accurate diagnosis through histopathology and molecular testing, and multidisciplinary collaboration are critical for optimizing treatment strategies in epithelioid sarcoma (ES), while future research into targeted therapies holds promise for improving outcomes, especially in advanced cases.
